Explorer les evidences

59,2 %Of the 135 HPV-positive women who were notified of their results, 77 (59.2%) sought treatment.

Kenyainfection à HPVobservé 2018publié 2021International journal of gynaecology and obstetrics: the official organ of the InternationPubMeddocument de 7 observations

90 %The rate of HPV seropositivity at 48 months was 90% for HPV-16.

Kenyainfection à HPVobservé 48 monthspublié 2021VaccinePubMeddocument de 7 observations

1 002 womenHome-based testing reached 1002 women aged 25–65 years in six communities in rural Western Kenya.

Kenyainfection à HPVpublié 2020BMJ openPubMeddocument de 4 observations

293 casesA total of 293 HPV-positive women living with HIV underwent thermal ablation in the study period.

Kenyainfection à HPVobservé August 2019 to February 2020publié 2020JCO global oncologyPubMeddocument de 14 observations

84,3 %Among 115 gbMSM in Nairobi, Kenya, HPV prevalence was 84.3% among those living with HIV.

Kenyainfection à HPVpublié 2023Cancer medicinePubMeddocument de 7 observations

The prevalence of high-risk HPV genotypes was statistically higher in the Botswana population compared to Kenya (p-value < 0.001).

Botswana · Kenyainfection à HPVpublié 2022BMC infectious diseasesPubMeddocument de 4 observations

9,4 %HPV vaccination coverage was 9.4% among adolescent girls in Western Kenya.

Kenyainfection à HPVpublié 2021The Pan African medical journalPubMeddocument de 5 observations

32,2 %Among 115 gbMSM in Nairobi, Kenya, one-third (32.2%) had high-risk HPV (HR-HPV).

Kenyainfection à HPVpublié 2023Cancer medicinePubMeddocument de 7 observations

47,6 %Among participants with high-risk HPV genotypes (n=82), 47.6% (39/82) were coinfected with HIV.

Kenyainfection à HPV · VIH/sidapublié 2022BMC infectious diseasesPubMeddocument de 4 observations

83 %The rate of HPV seropositivity at 48 months was 83% for HPV-6.

Kenyainfection à HPVobservé 48 monthspublié 2021VaccinePubMeddocument de 7 observations

42 %HPV vaccination could reduce the cervical cancer burden by 42–60 %.

Kenyacancer du col de l'utérus · infection à HPVpublié 2023VaccinePubMeddocument de 6 observations

75,84 %75.84% of health-care professionals thought that giving a single-dose of the HPV vaccine to adolescent girls and young women was either acceptable or very acceptable.

Kenyainfection à HPVpublié 2024Journal of the National Cancer Institute. MonographsPubMeddocument de 5 observations

97 daysHPV-positive women who did not receive treatment had a median time from screening to result notification of 97 days.

Kenyainfection à HPVobservé 2018publié 2021International journal of gynaecology and obstetrics: the official organ of the InternationPubMeddocument de 7 observations

77 %The rate of HPV seropositivity at 48 months was 77% for HPV-18.

Kenyainfection à HPVobservé 48 monthspublié 2021VaccinePubMeddocument de 7 observations

92 daysHPV-positive women who received treatment had a median time from screening to result notification of 92 days.

Kenyainfection à HPVobservé 2018publié 2021International journal of gynaecology and obstetrics: the official organ of the InternationPubMeddocument de 7 observations

16 %In 2020, only 16% of the targeted population in Kenya returned for the second dose of the HPV vaccine.

Kenyainfection à HPVobservé 2020publié 2022Frontiers in public healthPubMeddocument de 4 observations

16,3 %Among 98 HPV-positive cervical samples, 16.3% (16/98) had low-risk (LR) HPV genotypes.

Kenyainfection à HPVpublié 2022BMC infectious diseasesPubMeddocument de 4 observations

16,8 %Among 555 women (16.8%) who tested HPV-positive, 257 (46.3%) accessed treatment.

Kenyainfection à HPVpublié 2024BMC women's healthPubMeddocument de 5 observations

10 %Only 10% (105 out of 1027) of HPV-positive cases were triaged with VIA/VILI.

Kenyainfection à HPVpublié 2023PloS onePubMeddocument de 16 observations

22,4 %Women in the general population had an HPV positivity rate of 22.4%.

Kenyainfection à HPVpublié 2026BMC cancerPubMeddocument de 12 observations

10,3 %Women who reported engaging in commercial sex were less likely to test HPV positive compared to women in the general population (10.3% versus 22.4%, respectively).

Kenyainfection à HPVpublié 2026BMC cancerPubMeddocument de 12 observations

33 %In 2020, only 33% of the targeted population in Kenya received the first dose of the HPV vaccine.

Kenyainfection à HPVobservé 2020publié 2022Frontiers in public healthPubMeddocument de 4 observations

18,7 %Among the 749 women screened, 134 women (18.7%) were HPV-positive.

Kenyainfection à HPVpublié 2022BMC women's healthPubMeddocument de 7 observations

16 %A study from Kenya reported a low HPV vaccine second dose uptake of 16% in young girls during the COVID-19 pandemic.

Kenyainfection à HPVHAL · Unilimdocument de 69 observations